INSIGHTS ON DRUG DEVELOPMENT
-
Scale-Up Of A Transient rAAV Production Process
Scalable rAAV production is achievable with a transient cell line and optimized bioreactor setup, delivering high titers and reduced impurities, now validated at 200 L scale for commercial readiness.
-
5 Trends Impacting CMOs In 2025
In 2025, CMOs will navigate Annex 1 compliance, the BioSecure Act’s uncertainty, AI-driven drug development, supply chain challenges from tariffs, and pandemic preparedness strategies.
-
Unlock The Power Of Biophysical Tools In Biotherapeutic Development
Unlock innovation in biotherapeutics with expert insights into DSC and molecular stability. Learn how biophysical techniques can optimize formulations and enhance nucleic acid stability.
-
Ask Us Anything: Cy Credille
Learn how we balance discovery and development as an asset scales, and how the One Cambrex model keeps the original process scientists attached to a molecule from first kilos through NDA.
-
If Collaboration Fuels Biopharma Innovation, Why Can't We Connect More?3/17/2026
Breakthroughs thrive when biopharma teams work across silos, yet collaboration remains surprisingly difficult. Explore the barriers and why they persist. What will it take to move beyond them?
-
Assessing Developability And Designing Advanceable Formulations From The Start1/15/2026
Discover how early developability assessments and a quality-by-design approach can streamline formulation, reduce risk, and accelerate your path to successful, cost-effective drug development.
-
Redefining OSD Development Through Foresight And Innovation2/12/2026
From early formulation challenges to scale-up and commercial readiness, proactive planning and integrated capabilities help teams anticipate risks, accelerate decision-making, and maintain momentum across development.
-
NGS Identification Of Internal Tandem Duplications In FLT36/15/2026
Accurately identifying genetic duplications in leukemia requires more than conventional sequencing. See how advanced enrichment and analysis approaches enable deeper insight into variant structure.
-
Characterizing Quality Attributes Of GLP-1 Analogs By Light Scattering7/31/2025
Explore how light scattering reveals the structural integrity, aggregation, and stability of GLP-1 analogs to advance drug formulation and enhance treatment efficacy for type 2 diabetes and obesity.
DRUG DEVELOPMENT SOLUTIONS
-
Re-engineer your drug's path into clinical development and accelerate time to Proof-of-Concept. Real-time data guides rapid formulation iterations, minimizing drug substance use and lowering program risk.
-
A new collaboration helps to remove obstacles from the critical path, reduce development risks, eliminate the white space in pre-clinical drug development, and shorten the pathway to clinical development.
-
Explore an expansion service with experts that will work closely with you to customize your process and meet your unique needs by adjusting protocols, optimizing conditions, and providing personalized support.
-
Observe how comprehensive R&D support advances therapeutic oligonucleotides from discovery through commercialization with tailored formulation development services across multiple modalities and delivery platforms.
-
Sterility is key for high-risk applications such as injectables, parenteral formulations, ophthalmic and peritoneal dialysis solutions, and many more.